Chris Yoo

Director at Systems Oncology

Dr. Yoo has over 25 years of experience in advancing cutting-edge biomedical information technology. He is the founder and CEO of Systems Imagination, Inc., which offers advanced cognitive computing technology to translate big data into valuable insights. At IBM, he was instrumental as Head of Strategy and Planning for IBM’s Information Based Medicine business, a new unit that pioneered the infusion of high-performance computing and research into the nascent fields of personalized medicine and molecular therapeutics based on genomics. Throughout his career, he has also held leadership positions at Cisco, Oracle, and Applied Biosystems.

As a serial entrepreneur, Dr. Yoo has created value in new companies that accelerate the adoption of smarter, technology-based systems such as cognitive computing, big data analytics, and knowledge engineering. He has founded and successfully engineered the exit of startups including MedTrust Online, the world’s first and largest online community of cancer doctors treating difficult cases with molecular medicine knowledge. He has also founded Golden Gateway Partners, a trans-Pacific technology consulting company, TransMed Partners, the first boutique consultancy for translational medicine, and LabBook, the first electronic laboratory notebook for HCLS researchers.

In addition to his leadership roles at Systems Oncology and Systems Imagination, Dr. Yoo is also a Faculty Associate in the College of Health Solutions at Arizona State University. Dr. Yoo received his Ph.D. in Cell and Molecular Biology from Yale University and completed his postdoctoral fellowship at UC Berkeley.

Location

Phoenix, United States

Links


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Systems Oncology

1 followers

Systems Oncology is developing a new class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance.


Industries

Employees

11-50

Links